Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 2:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 4,271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ADM Clear all

Conditions: Meningococcal Vaccine
Interventions: Awareness, Education, Empowerment, Accessibility; Other
Lead sponsor: University of Florida; Other
Eligibility: 16 Years to 99 Years
Enrollment: 1,326 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 6
States / cities: Gainesville, Florida

Conditions: Adhesive Capsulitis, Frozen Shoulder, Shoulder Frozen
Interventions: Physical Therapy, Depot Methylprednisolone; Other · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoarthritis, Knee, Hypertension
Interventions: STAR Intervention, Attention-Control; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 50 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Blood Pressure, Hypertension, Mhealth
Interventions: PACESETTER; Device
Lead sponsor: Northern California Institute of Research and Education; Other
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 4
States / cities: San Francisco, California • Charleston, South Carolina • Columbia, South Carolina + 1 more

Conditions: Neutrophil Chemotactic Response
Interventions: Exercise, ProLab 200mg caffeine capsule, Ethanol ingestion, Glucose Tolerance Drink; Behavioral · Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years to 60 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Sarcoma
Interventions: Doxorubicin hydrochloride (DOX), Conventional surgery, Intraoperative radiation therapy (IORT), Radiation Therapy (RT); Drug · Procedure · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Tobacco Use Cessation
Interventions: Brief telephone advice plus tailored text messages, Mailed nicotine replacement therapy, Proactive telephone coaching; Behavioral · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Insomnia, Coronary Heart Disease
Interventions: Go! to Sleep, General Sleep Education; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Functional Chest Pain
Interventions: Home Hypnotherapy, Educational; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Chest Pain
Interventions: Full counseling, Minimal counseling; Behavioral
Lead sponsor: David A Katz; Other
Eligibility: 30 Years to 100 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Asthma, COPD (Chronic Obstructive Pulmonary Disease)
Interventions: Air Cleaner, PM2.5 Monitor with Visual Air Quality Indicator, Educational Materials, Air Cleaner Technical Assistance; Device · Behavioral
Lead sponsor: University of California, Berkeley; Other
Eligibility: 13 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Berkeley, California • San Francisco, California

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: bortezomib, pegylated liposomal doxorubicin hydrochloride, thalidomide; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Cardiac Toxicity, Lymphoma
Interventions: bleomycin sulfate, filgrastim, cyclophosphamide, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2008
U.S. locations: 57
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 45 more

Conditions: Acute Lymphoblastic Leukemia
Interventions: prednisone, dexamethasone, doxorubicin, E. coli asparaginase, vincristine, methotrexate, Leucovorin, Asparaginase, cytarabine, Methotrexate/Hydrocortisone; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 1 Year to 18 Years
Enrollment: 498 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Docetaxel,doxorubicin, cyclophosphamide; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 3,299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2013
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Parathyroid Adenoma, Parathyroid Neoplasms, Parathyroid Hyperplasia, Parathyroid Cancer, Hypercalcemia, Primary Hyperparathyroidism
Interventions: NIRAF Detection Technology; Device
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Relapsed Sarcomas
Interventions: Disulfiram, Copper Gluconate, Liposomal Doxorubicin (Doxil); Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Lymphoma
Interventions: Bleomycin sulfate, Stanford V regimen, Doxorubicin hydrochloride, Etoposide, Mechlorethamine hydrochloride, Prednisone, Vinblastine, Vincristine sulfate; Biological · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Pre Diabetes
Interventions: Automated educational text messages, Autonomy-supportive automated educational text messages, Financial incentives, Tailored text messages; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: CF Therapeutics Development Network Coordinating Center; Network
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Birmingham, Alabama • Iowa City, Iowa • Chapel Hill, North Carolina

Conditions: Small Cell Lung Cancer, Pancreatic Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer
Interventions: Topotecan and pegylated doxorubicin; Drug
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Suicide, Attempted, Substance-Related Disorders
Interventions: Cognitive Therapy, Enriched Care; Behavioral · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Down Syndrome, Cardiovascular Risk Factor, Atherosclerosis
Interventions: Evaluate vascular disease risk factors in children with Down Syndrome, Determine the associations between cardiovascular disease risk factors and markers of early atherosclerosis in children with Down Syndrome; Other
Lead sponsor: University of Utah; Other
Eligibility: 10 Years to 18 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions: Dinaciclib, Epirubicin Hydrochloride, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

MenB Vaccine: Implementation Via Information, Empowerment and Accessibility

Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment

Staying Active With Arthritis: RCT of Physical Activity for Older Adults With Osteoarthritis and Hypertension

PACESETTER: Program to Avoid Cerebrovascular Events Through Systematic Electronic Tracking and Tailoring of an Eminent Risk-factor

Influence of Lifestyle Factors on Neutrophil Migration Pilot Study

Radiation Therapy Plus Doxorubicin in Treating Patients With Resectable Primary or Recurrent Retroperitoneal Soft Tissue Sarcoma

Engagement With an Adaptive Mobile Health Smoking Cessation Intervention

Improving Sleep for Healthy Hearts

Home Hypnotherapy for Refractory Functional Chest Pain: A Pilot Study

Chest Pain Observation Unit Risk Reduction Trial

Reducing Exposure With Air Cleaners and Technology

Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

Treatment of Acute Lymphoblastic Leukemia in Children

Docetaxel in Breast Cancer

Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy

Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas

Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma

Behavioral Economics and Self-Determination Theory to Change Diabetes Risk (BEST Change)

Detection of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity in Rectal Tissues From Human Subjects

Doxil Topotecan Doublet Cancer Study

Effectiveness of Cognitive Therapy for Suicide Attempters With Drug Dependence Disorder

Vascular Health and Risk Factors in Children With Down Syndrome

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer